CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
9.10
+0.61 (7.18%)
At close: May 12, 2025, 4:00 PM
8.75
-0.35 (-3.85%)
After-hours: May 12, 2025, 7:41 PM EDT
Company Description
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery.
The company develops EIP200 for central nervous system which is in preclinical trials. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John Alam |
Contact Details
Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States | |
| Phone | 617 744 4400 |
| Website | cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder and Director |
| William Robert Elder J.D. | Chief Financial Officer, General Counsel and Corporate Secretary |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Chief Operating Officer and Director |
| Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |
| Dr. Mark A. De Rosch Ph.D. | Executive Vice President of Regulatory, Government Affairs and Program Management |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 424B5 | Filing |
| May 12, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | SCHEDULE 13G | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 17, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |